Document is current
Any future updates will be listed below
-
Authors
Pradier, Laurent http://orcid.org/0000-0001-6022-0951
Blanchard-Brégeon, Véronique
Bohme, Andrees
Debeir, Thomas
Menager, Jean
Benoit, Patrick
Barneoud, Pascal
Taupin, Véronique
Bertrand, Philippe
Dugay, Philippe
Cameron, Béatrice
Shi, Yi
Naimi, Souad
Duchesne, Marc
Gagnaire, Marie
Weeden, Tim
Travaline, Tara
Reczek, David
Khiroug, Leonard
Slaoui, Mohamed
Brunel, Pascale
Fukuyama, Hidehiro
Ravetch, Jeffrey
Canton, Thierry
Cohen, Caroline
-
Funding
Funding for this research was provided by:
sanofi employee
- License Information
-
More Information
Article History
Received: 11 April 2018
Accepted: 4 November 2018
First Online: 28 November 2018
Ethics approval
: Animal studies have been validated by an internal ethics committee (see Methods section).Experiments were performed at Sanofi in an AAALAC-accredited facility in full compliance with the standards for the care and use of laboratory animals, according to French and European Community (Directive 2010/63/EU) legislation. All procedures were approved by the local Animal Ethics Committee (CEEA #24) and the French Ministry for Research.
: Not applicable.
: HK and JR are inventors on patent application W02009/065054 describing the murine antibody 13C3 from which the antibodies described in this manuscript are derived. Sanofi hold a license to the derived intellectual property. LK, Neurotar Ltd., performed this work as part of a research contract with Sanofi.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
